MBM-02 (Tempol)

Tempol · Matrix Biomed, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for MBM-02 (Tempol), covering 2021-05-06 to 2021-05-06. Get the full timeline:

Most recent: Clinical Trial Update: MBM-02 (Tempol) for the Treatment of Biochemical Recurrent Prostate Cancer [Phase 2]